Agents and Actions

, Volume 27, Issue 3–4, pp 473–476 | Cite as

An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats

  • D. W. Howat
  • N. Chand
  • P. Braquet
  • D. A. Willoughby
Mini-Papers Submitted for Scholarship Competition Lipids, PLA2 and PAF

Abstract

Rats developing experimental allergic encephalomyelitis have been treated with intra-venous injections of Platelet-Activating Factor on days 5,6 and 7 post adjuvant injection. Other rats have been treated with one of two different PAF antagonists or vehicle. The animals injected with PAF on day 5 post adjuvant developed a more severe form of the disease at an earlier time point than did control animals. Animals treated with the PAF antagonists did not develop the disease to any great extent. Treatment with the vehicle had no effect compared to control. These results implicate PAF in the aetiology of this model of multiple sclerosis and may suggest a role for PAF antagonists in the treatment of this disease.

Keywords

Multiple Sclerosis Control Animal Early Time Activate Factor Platelet Activate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    C. Archer, C. Page, J. Morley and D. Macdonald,Early and late inflammatory effects of PAF in skin of experimental animals and man. J. Invest. Dermatol.80, 347 (1983).Google Scholar
  2. [2]
    E. Pirotsky, C. Page, R. Roubin, A. Pfister, W. Paul, J. Bonnet and J. Benveniste,PAF-acether induced plasma exudation in rat skin is independent of platelets an neutrophils. Microcirculation, Endothelium and Lymphatics1, 107 (1984).Google Scholar
  3. [3]
    E. Korneki, Y. H. Erhlich, R. H. Lenox, and D. H. Hardwick,A role for platelet activating factor in neuronal function: inhibition of platelet activation by triazolobenzodiazepines and interaction of PAF with cultured neural cells. InProceedings of the meeting “The promise of PAF”, London 1986.Google Scholar
  4. [4]
    C. Martin-Mondiere, D. Charron, B. Spinnewyn and P. Braquet,HMC in central nervous system: modulation of expression by PAF-acether. Prostaglandins34, 163 (1987).Google Scholar
  5. [5]
    J. W. Prineas InHandbook of clinical neurology. Vol. 3. (Eds. P. J. Vinken, G. W. Bruyn and H. L. Klawans) pp. 213–257, Elsevier, New York 1985.Google Scholar
  6. [6]
    I. V. Allen, InGreenfield's neuropathology, 4th Edn. (Eds. J. A. Adams, J. A. N. Corsellis and L. W. Duchen) pp. 338–384. Arnold, London 1984.Google Scholar
  7. [7]
    B. H. Waksman and R. D. Adams,A histologic study of the early lesion in experimental allergic encephalomyelitis in the guinea pig and rabbit. Am. J. Pathol.41, 135–162 (1962).Google Scholar
  8. [8]
    S. Lightman, W. McDonald, A. Bird, D. Francis, A. Hoskins, J. Batchlor and A. Halliday,Retinal venous sheating in optic neuritis. Brain110, 405–414 (1987).Google Scholar
  9. [9]
    P. Braquet,The Ginkgolides: Potent platelet-activating factor antagonists isolated from ginkgo biloba L.: Chemistry, pharmacology and clinical applications. Drugs of the Future12, 643–699 (1987).Google Scholar
  10. [10]
    P. Braquet, L. Touqui, T. Y. Shen and B. B. Vargaftig,Perspectives in platelet-activating factor research. Pharmacol. Rev.39, 97–145 (1987).Google Scholar
  11. [11]
    C. S. Raine, L. B. Barnett, A. Brown, T. Behar and D. E. McFarlin,Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab. Invest.43, 150 (1980).Google Scholar
  12. [12]
    M. Vulpe, A. Hawkins and B. Rozdilsky,Permeability of cerebral blood vessels in experimental allergic encephalomyelitis studied by radioactive iodinated bovine albumin. Neurology10, 171 (1960).Google Scholar
  13. [13]
    R. Cutler, A. Lorenzo and C. Barlow,Brain vascular permeability to 125 I, gamma globulin and leukocytes in allergic encephalomyelitis. J. Neuropath. Exp. Neurol.26, 558 (1967).Google Scholar
  14. [14]
    P. Daniel, D. Lam and O. Pratt,Changes in the effectiveness of the blood-brain and blood-spinal cord barriers in experimental allergic encephalomyelitis. Possible relevance to multiple sclerosis. J. Neurol. Sci.52, 211 (1981).Google Scholar
  15. [15]
    A. Suckling, H. Reiber, J. Kirby and M. Rumsby,Chronic relapsing experimental encephalomyelitis: Immunological and blood-cerebrospinal fluid barrier dependent changes in the cerebrospinal fluid. J. Neuroimmunol.4, 35 (1983).Google Scholar
  16. [16]
    N. Tsukada, C. S. Koh, N. Yanagisawa, P. Okano, W. M. Behan and P. O. Behan,A new model for multiple sclerosis: Chronic experimental allergic encephalomyelitis induced by immunisation with cerebral endothelial cell membrane. Acta. Neuropathol.73, 259 (1987).Google Scholar
  17. [17]
    C. E. Wilcox, D. W. Howat, F. M. Desa, A. R. Moore and D. A. Willoughby,PAF-acether: a possible mediator of autoimmune diseases. Prostaglandins34, 164 (1987).Google Scholar
  18. [18]
    B. Spinnewyn, N. Blavet, F. Clostre, N. Bazan and P. Braquet,Involvement of platelet-activating factor in cerebral post-ischemic phase in Mongolian gerbils. Prostaglandins34, 337 (1987).Google Scholar
  19. [19]
    A. J. Suckling, H. Reiber, J. A. Kirby and M. G. Rumbsy,Blood-cerebrospinal fluid barrier permeability changes in guinea pigs inoculated for chronic relapsing experimental encephalomyelitis or with adjuvant alone. InProgress in clinical and biological research, vol. 146. (Eds. E. Alvord, M. Kies and A. Suckling) pp. 75–80, A. R. Liss. Inc., New York 1984.Google Scholar
  20. [20]
    S. G. Ward, G. P. Lewis and J. Westwick,Differential effects of platelet-activating factor receptor antagonists on human T-lymphocyte proliferation. Prostaglandins34, 149 (1987).Google Scholar
  21. [21]
    M. Rola-Pleszczynski, B. Pignol, C. Poulet and P. Braquet,Inhibition of human lymphocyte proliferation and interleukin-2 production by platelet activating factor: reversal by a specific antagonist BN52021. Biochem. Biophys. Res. Commun.142, 754–760 (1987).Google Scholar
  22. [22]
    M. Rola-Pleszczynski and S. Turcotte,Activation of suppressor lymphocytes and monocytes by PAF-acether. Prostaglandins34, 148 (1987).Google Scholar

Copyright information

© Birkhäuser Verlag 1989

Authors and Affiliations

  • D. W. Howat
    • 1
  • N. Chand
    • 1
  • P. Braquet
    • 2
  • D. A. Willoughby
    • 1
  1. 1.Department of Experimental Pathology St.Bartholomew's Hospital Medical CollegeLondonUK
  2. 2.I. H. B. Research LaboratoriesParisFrance

Personalised recommendations